Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI8897 (Nirsevimab) in Healthy Preterm Infants
NCT02290340Phase 1Completed
- Sponsor
- MedImmune
- Start
- Jan 2015
- Primary completion
- Sep 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of nirsevimab in respiratory syncytial virus infection (RSV) (4 arms), sponsored by MedImmune. Primary endpoints: Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events, Treatment-Emergent Adverse Events of Special Interest and 1 more. Started Jan 2015; status: completed.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02290340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02290340.